3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Bevacizumab
3
pralsetinib
2
pembrolizumab
2
osimertinib
2
contrast agent BR1
2
Pemetrexed
2
Oncolytic Virotherapy
2
Carboplatin
2
vorasidenib
1
interferon gamma-1b
1
Paclitaxel
1
Microbubbles
1
Interferon-gamma
1
Immunotherapy
1
Gemcitabine
1
Cisplatin
1
Antibodies, Monoclonal
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Nerve Tissue
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled